作为用于治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂的新型三唑并吡啶衍生物
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Aug 21;15(9):1435-1436. doi: 10.1021/acsmedchemlett.4c00408. eCollection 2024 Sep 12.
Abstract
Provided herein are novel triazolopyridine derivatives as DGAT2 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.
摘要
本文提供了作为二酰甘油酰基转移酶2（DGAT2）抑制剂的新型三唑并吡啶衍生物、药物组合物、此类化合物在治疗多种疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Aug 21;15(9):1435-1436. doi: 10.1021/acsmedchemlett.4c00408. eCollection 2024 Sep 12.
2
Pyrazolopyridine and Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Oct 14;15(11):1806-1807. doi: 10.1021/acsmedchemlett.4c00485. eCollection 2024 Nov 14.
3
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Jul 3;15(8):1180-1181. doi: 10.1021/acsmedchemlett.4c00286. eCollection 2024 Aug 8.
4
Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives.
ACS Med Chem Lett. 2024 Jul 25;15(8):1199-1200. doi: 10.1021/acsmedchemlett.4c00329. eCollection 2024 Aug 8.
5
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
6
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
7
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
8
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Jun 21;15(7):994-995. doi: 10.1021/acsmedchemlett.4c00261. eCollection 2024 Jul 11.
9
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
10
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
引用本文的文献
1
Pyrazolopyridine and Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Oct 14;15(11):1806-1807. doi: 10.1021/acsmedchemlett.4c00485. eCollection 2024 Nov 14.
本文引用的文献
1
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Jul 3;15(8):1180-1181. doi: 10.1021/acsmedchemlett.4c00286. eCollection 2024 Aug 8.
2
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Metabolism. 2024 Aug;157:155937. doi: 10.1016/j.metabol.2024.155937. Epub 2024 May 21.
3
Perilipins: A family of five fat-droplet storing proteins that play a significant role in fat homeostasis.
J Cell Biochem. 2024 Jun;125(6):e30579. doi: 10.1002/jcb.30579. Epub 2024 May 15.
4
The lipid droplet lipidome.
FEBS Lett. 2024 May;598(10):1215-1225. doi: 10.1002/1873-3468.14874. Epub 2024 Apr 11.
5
The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications.
J Transl Med. 2024 Mar 18;22(1):290. doi: 10.1186/s12967-024-05084-z.
6
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
J Hepatol. 2024 Feb;80(2):362-377. doi: 10.1016/j.jhep.2023.10.042. Epub 2023 Nov 15.
Zotero 插件